Other Clinical Trial - MIYOPERİCYTOMA OF ORAL MUCOSE: CASE REPORT

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Completed

Clinical Trial Summary

Miyopericytoma (MPC) is defined as a benign tumor consisting mostly of oval-spindle-shaped myoid-appearing cells with perivascular growth. It may involve a single or multiple anatomical regions and may be multifocal and tends to occur mainly in the extremities, dermal and superficial soft tissues of adults. Cases of miyopericytoma due to trauma have been reported.Histological features and clinical course are generally benign, but features suggestive of low-grade malignancy were seen in MPCs. Myopericytoma in the oral and maxillofacial region is rare and a limited number of cases have been reported in the literature. A 42-year-old female patient was admitted to our clinic with an enlarging lesion on the lingual aspect of the anterior mandible, which she noticed 2 years ago. As a result of the examination, a smooth-surfaced, off-white, pedunculated, fibrotic, painless, and non-bleeding lesion was detected in the lingual aspect of the anterior mandible. The lesion was removed by excisional biopsy.

Clinical Trial Description

n/a

Study Design

Clinical Trial Details

NCT number	NCT05126420
Study type	Observational
Source	Ankara University
Contact
Status	Completed
Phase
Start date	January 1, 2020
Completion date	January 1, 2021

View Details